Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Burnett

Showing results (1-10 of 157) with videos related to

Pageof 16
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2005
Torcetrapib + atorvastatin (Pfizer)John R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|September 28, 2006
Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemiaJohn R Burnett
Idrugs : the Investigational Drugs Journal|July 6, 2006
Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemiaJohn R Burnett
Critical Reviews in Clinical Laboratory Sciences|December 11, 2012
Critical Reviews in Clinical Laboratory Sciences: parting comments from the Editor-in-ChiefJohn R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
FM-VP4 Forbes Medi-TechJohn R Burnett
Idrugs : the Investigational Drugs Journal|October 31, 2007
Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuriaJohn R Burnett
The Clinical Biochemist. Reviews|June 3, 2008
Lipids, lipoproteins, atherosclerosis and cardiovascular diseaseJohn R Burnett
Pathology|February 14, 2024
Pathology: evolution not revolutionJohn R Burnett
Current Opinion in Molecular Therapeutics|November 3, 2006
Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemiaJohn R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Eflucimibe. Pierre Fabre/Eli LillyJohn R Burnett
Pageof 16

Showing results (1-10 of 157) with videos related to

Sort By:
Pageof 16
Current Opinion in Investigational Drugs (London, England : 2000)|September 29, 2005
Torcetrapib + atorvastatin (Pfizer)John R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|September 28, 2006
Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemiaJohn R Burnett
Idrugs : the Investigational Drugs Journal|July 6, 2006
Drug evaluation: The MTP inhibitor JTT-130 as a potential treatment for hyperlipidemiaJohn R Burnett
Critical Reviews in Clinical Laboratory Sciences|December 11, 2012
Critical Reviews in Clinical Laboratory Sciences: parting comments from the Editor-in-ChiefJohn R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|October 30, 2003
FM-VP4 Forbes Medi-TechJohn R Burnett
Idrugs : the Investigational Drugs Journal|October 31, 2007
Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuriaJohn R Burnett
The Clinical Biochemist. Reviews|June 3, 2008
Lipids, lipoproteins, atherosclerosis and cardiovascular diseaseJohn R Burnett
Pathology|February 14, 2024
Pathology: evolution not revolutionJohn R Burnett
Current Opinion in Molecular Therapeutics|November 3, 2006
Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemiaJohn R Burnett
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Eflucimibe. Pierre Fabre/Eli LillyJohn R Burnett
Pageof 16